Summio

Book

Bad Blood

An investigative journalist's account of the rise and fall of Theranos, a biotech startup that promised revolutionary blood testing technology.

21 min read

Available in

Summary preview

Bad Blood: A Deep Dive into Theranos's Rise and Fall John Carreyrou's "Bad Blood" chronicles the meteoric rise and catastrophic fall of Theranos, a biotech startup founded by Elizabeth Holmes, who promised to revolutionize blood testing with a single drop of blood. The book details how Holmes, a charismatic Stanford dropout, cultivated an image of genius and raised over $700 million from elite investors, valuing Theranos at $9 billion. However, Carreyrou's investigative journalism reveals that the core technology, the 'Edison' machine, was fundamentally flawed and unreliable. To maintain the facade, Theranos secretly used modified commercial machines, often diluting patient samples, leading to potentially inaccurate results. The company culture was characterized by extreme secrecy, intimidation, and the suppression of dissent. Holmes's partner, Ramesh 'Sunny' Balwani, played a key role in the company's aggressive management and operations. Early employees, disillusioned by the technological failures and deception, became whistleblowers, risking their careers to expose the truth. Carreyrou faced immense pressure and legal threats from Theranos while meticulously investigating the company, relying on these courageous insiders. His groundbreaking reporting in The Wall Street Journal in 2015 triggered regulatory investigations by the SEC and CMS, numerous lawsuits, and the collapse of Theranos's partnerships, notably with Walgreens. By 2018, Theranos dissolved, and Holmes and Balwani were indicted and subsequently convicted of fraud. The book explores key themes including the dangers of charismatic leadership, the excesses of Silicon Valley's 'unicorn' culture, the critical importance of scientific integrity and due diligence, the manipulative use of secrecy, and the vital role of whistleblowers and investigative journalism. It delves into the personalities of Holmes and Balwani, portraying them as central figures in the elaborate deception. The technological failures of the 'Edison' machine, its limited capabilities, and the reliance on borrowed, modified equipment are thoroughly examined. "Bad Blood" offers critical lessons for investors, entrepreneurs, employees, and consumers, emphasizing the paramount importance of integrity, transparency, and ethical responsibility in innovation, especially within the high-stakes healthcare sector. The Theranos phenomenon is contextualized within the rise of the 'unicorn' culture, the influence of prestigious but perhaps uninformed board members, and the testing of Silicon Valley's 'move fast and break things' ethos. The book serves as a cautionary tale about building empires on lies and the inevitable consequences of unchecked corporate hubris. Section 1: The Genesis of a Revolution (Or So We Thought) Elizabeth Holmes, a young Stanford dropout, envisioned a revolutionary blood-testing device, the 'Edison,' capable of performing hundreds of tests from a tiny finger prick. This promised to disrupt traditional